Notes to editor
This press release accompanies both a presentation and an ESC press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
Funding: The trial was sponsored by Ionis Pharmaceuticals.
Disclosures: Doctor Bergmark reports grant support through his institution from Ionis, Pfizer, Abbott Vascular, Philips, Inari, AstraZeneca, MedImmune and Amgen; and consulting/personal fees from Shockwave, Abbott Vascular, Abiomed, Bain Life Sciences, Bolt, Terumo, SpectraWAVE, CSI and Endovascular Engineering.
References and notes:
1‘Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk: the Essence-TIMI 73b trial’ presented during HOT LINE 4 on 30 August 2025 at 16:45 to 16:55 in Madrid (Main Auditorium) and simultaneously published in New England Journal of Medicine
2Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for hypertriglyceridemia in patients at high cardiovascular risk. N Engl J Med. 2024;390:1770−1780.
3Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401−1412.
4Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390:1781−1792.
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.